GSK2556286

Synonym(s): GSK286

Class: Substituted 4-aryloxypiperidine

Details of activity:	Active against Mycobacterium tuberculosis; ongoing studies to evaluate mode of action but potential cholesterol-dependent mode of action
Propensity to select resistant mutants:	Yes
Description:	Synthetic novel small-molecule
Institute where first reported:	GlaxoSmithKline
Year first mentioned:	2022
Highest developmental phase:	Phase 1 (NCT04472897)
Development status:	Active (as of 2023)

Chemical structure(s):
Canonical SMILES:	CC1=CC=CC(=C1C)OC2CCN(CC2)CC3=CC(=O)NC(=O)N3
Isomeric SMILES:	CC1=C(C(=CC=C1)OC2CCN(CC2)CC3=CC(=O)NC(=O)N3)C
InChI:	InChI=1S/C18H23N3O3/c1-12-4-3-5-16(13(12)2)24-15-6-8-21(9-7-15)11-14-10-17(22)20-18(23)19-14/h3-5,10,15H,6-9,11H2,1-2H3,(H2,19,20,22,23)
InChI Key:	AZOFJHATIPDIER-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/45833762

External links:
Guide to Pharmacology:	GSK2556286
Main Source:	https://journals.asm.org/doi/10.1128/aac.00132-22